Copyright
©The Author(s) 2024.
World J Diabetes. Mar 15, 2024; 15(3): 361-377
Published online Mar 15, 2024. doi: 10.4239/wjd.v15.i3.361
Published online Mar 15, 2024. doi: 10.4239/wjd.v15.i3.361
Trial population | Prescribed dosage | Associated or not | Treatment cycle | Reversal rate | Ref. |
Adolescents | 1000 mg/d | Rosiglitazone (2 mg) | 3.9 yr | 80% improvement in glucose tolerance | Zinman et al[137] |
Adolescents | 1000 mg/d | No | 6 months | 45% increase in insulin sensitivity | Srinivasan et al[138] |
Adults | 850 mg/d | No | 1 yr | 7% reduction in the incidence of diabetes | Andreadis et al[139] |
Adults | 2000 mg/d | No | 1 yr | Increased insulin sensitivity (P < 0.01) | Malin et al[134] |
Adults | 1500-2000 mg/d | Exenatide (10-20 μg/d) | 1 yr | 64% improvement in prediabetes remission rates | Tao et al[140] |
- Citation: Ping WX, Hu S, Su JQ, Ouyang SY. Metabolic disorders in prediabetes: From mechanisms to therapeutic management. World J Diabetes 2024; 15(3): 361-377
- URL: https://www.wjgnet.com/1948-9358/full/v15/i3/361.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i3.361